Socar: A Promising Drug Target and Biomarker for Ovarian Cancer

Target Name: SOCAR

NCBI ID: G105373557

SOCAR

Other Name(s): Serous ovarian cancer associated RNA | serous ovarian cancer associated RNA

Socar: A Promising Drug Target and Biomarker for Ovarian Cancer

Socar (Serous Ovarian Cancer Associated RNA) is a promising drug target and biomarker for the treatment of ovarian cancer. Socar is a type of RNA that is expressed in the serous ovarian cancer, which is the most common type of ovarian cancer. According to a study by the National Cancer Institute, the survival rate for ovarian cancer has decreased by 12% since the 1990s, and current treatments are often effective in slowing the disease's progression. However, there is still a need for more effective and targeted treatments to improve outcomes.

Socar is a non-coding RNA molecule that has been identified as a potential drug target in ovarian cancer. It is expressed in the serous ovarian cancer and has been shown to be downregulated in other types of ovarian cancer. Socar has also been shown to play a role in the development and progression of ovarian cancer, and may be a useful biomarker for the disease.

One of the key advantages of Socar as a drug target is its expression in ovarian cancer cells. Unlike many other potential drug targets, Socar is expressed in a specific type of cancer cell, which makes it a more targeted and effective treatment option. Additionally, Socar has been shown to be expressed in different types of ovarian cancer, which may make it a useful biomarker for the disease.

Another potential advantage of Socar as a drug target is its role in the development and progression of ovarian cancer. Studies have shown that Socar is involved in the development of ovarian cancer by promoting the growth and survival of cancer cells. Additionally, Socar has been shown to contribute to the progression of ovarian cancer by promoting the development of new blood vessels that supply the cancer cells with oxygen and nutrients.

Socar may also be a useful biomarker for ovarian cancer because of its expression in different types of ovarian cancer. This makes it a more sensitive and accurate indicator of the severity and stage of the disease. For example, studies have shown that Socar is downregulated in ovarian cancer cells, which may make it a useful biomarker for early-stage disease. Additionally, Socar has been shown to be downregulated in ovarian cancer cells that are resistant to chemotherapy, which may make it a useful biomarker for monitoring the effectiveness of chemotherapy.

In conclusion, Socar is a promising drug target and biomarker for the treatment of ovarian cancer. Its expression in the serous ovarian cancer and its role in the development and progression of the disease make it a more targeted and effective treatment option. Additionally, Socar may be a useful biomarker for ovarian cancer due to its expression in different types of cancer and its contribution to the progression of the disease. Further research is needed to fully understand the potential of Socar as a drug target and biomarker for ovarian cancer.

Protein Name: Serous Ovarian Cancer Associated RNA

The "SOCAR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SOCAR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets